These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8788829)

  • 21. Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution.
    Randall SR; Adams LG; White MR; DeNicola DB
    Am J Vet Res; 1996 Jul; 57(7):1054-8. PubMed ID: 8807021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections.
    Sachs-Barrable K; Lee SD; Wasan EK; Thornton SJ; Wasan KM
    Adv Drug Deliv Rev; 2008 Mar; 60(6):692-701. PubMed ID: 18053611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pulmonary mucormycosis: benefit of aerosol amphotericin B?].
    Furco A; Mouchet B; Carbonnelle M; Vallerand H
    Rev Mal Respir; 2001 Jun; 18(3):309-13. PubMed ID: 11468594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study.
    Souza LC; Saldiva PH; Campa A
    Exp Toxicol Pathol; 2000 May; 52(2):169-75. PubMed ID: 10965993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical guidelines for preparing and administering amphotericin B.
    Kintzel PE; Smith GH
    Am J Hosp Pharm; 1992 May; 49(5):1156-64. PubMed ID: 1595747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
    Ho KM; Duff O; Chambers D; Murray R
    Transpl Infect Dis; 2008 Jun; 10(3):168-76. PubMed ID: 18194368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients.
    Barquist E; Fein E; Shadick D; Johnson J; Clark J; Shatz D
    J Trauma; 1999 Aug; 47(2):336-40. PubMed ID: 10452470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Amphotericin B and lipids: a new formulation].
    Ordóñez J; García A; Ferrándiz R
    Nutr Hosp; 1994; 9(2):114-5. PubMed ID: 8031949
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis.
    Sundar S; Singh A; Agarwal D; Rai M; Agrawal N; Chakravarty J
    Am J Trop Med Hyg; 2009 May; 80(5):700-3. PubMed ID: 19407109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion.
    Lopez RM; Ayestaran A; Pou L; Montoro JB; Hernandez M; Caragol I
    Am J Health Syst Pharm; 1996 Nov; 53(22):2724-7. PubMed ID: 8931814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Precipitation of amphotericin B from i.v. fat emulsion.
    Heide PE
    Am J Health Syst Pharm; 1997 Jun; 54(12):1449. PubMed ID: 9194992
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.
    Nucci M; Loureiro M; Silveira F; Casali AR; Bouzas LF; Velasco E; Spector N; Pulcheri W
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1445-8. PubMed ID: 10348768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Safety of long-term administration of conventional amphotericin B in oncology patients].
    Doubek M; Mayer J; Horký D
    Cas Lek Cesk; 2002 Mar; 141(5):156-9. PubMed ID: 11998223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.
    Paterson DL; David K; Mrsic M; Cetkovsky P; Weng XH; Sterba J; Krivan G; Boskovic D; Lu M; Zhu LP;
    J Antimicrob Chemother; 2008 Dec; 62(6):1392-400. PubMed ID: 18812423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.
    Sorkine P; Nagar H; Weinbroum A; Setton A; Israitel E; Scarlatt A; Silbiger A; Rudick V; Kluger Y; Halpern P
    Crit Care Med; 1996 Aug; 24(8):1311-5. PubMed ID: 8706484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.